We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,862

A Refresher on Re-Examination Estoppel
  • McDermott Will & Emery
  • USA
  • June 26 2017

Addressing the pre-AIA estoppel provision of 35 USC 317(b), the US Court of Appeals for the Federal Circuit affirmed a Patent Trial and Appeal


Attempt to Set Aside Judgment Yields Exceptional Case Award
  • McDermott Will & Emery
  • USA
  • June 26 2017

The US Court of Appeals for the Federal Circuit found that the district court did not abuse its discretion in awarding fees to the prevailing


The Right Test for Evaluating Equivalence in Chemical Cases
  • McDermott Will & Emery
  • USA
  • June 26 2017

The US Court of Appeals for the Federal Circuit affirmed a rare grant of preliminary injunction based on one of three patents in suit, but reversed


Conditional Covenant Not to Sue Insufficient to Moot Patent Dispute
  • McDermott Will & Emery
  • USA
  • June 26 2017

The US Court of Appeals for the Federal Circuit affirmed a summary judgment of non-infringement based on invalidity of asserted reissue claims as


Biosimilar Notice May Be Given Prior to FDA Approval
  • McDermott Will & Emery
  • USA
  • June 26 2017

In a unanimous decision, the Supreme Court of the United States explained that under the Biologics Price Competition and Innovation Act of 2009


No En Banc Resolution on Whether Patent Right Is Public Right
  • McDermott Will & Emery
  • USA
  • June 26 2017

In a 10-2 decision that included two concurrences and two dissents, the US Court of Appeals for the Federal Circuit denied a patent owner's petition


Supreme Court Analyzes Key Provisions of Biologics Price Competition and Innovation Act of 2009
  • McDermott Will & Emery
  • USA
  • June 20 2017

In a unanimous decision, the United States Supreme Court has clarified certain portions of the Biologics Price Competition and Innovation Act


Supreme Court to Patent Holders: Sell Product Anywhere, Exhaust Patent Rights Everywhere
  • McDermott Will & Emery
  • USA
  • June 1 2017

Reversing long-standing Federal Circuit precedent, the United States Supreme Court has now held that a patentee extinguishes its patent


No Due Process Violation in PTAB’s Treatment of References
  • McDermott Will & Emery
  • USA
  • May 25 2017

Addressing issues of procedural due process and obviousness, the US Court of Appeals for the Federal Circuit affirmed a Patent Trial and Appeal Board


Inter Partes Re-Examination Estoppel Saves Rejected Claims
  • McDermott Will & Emery
  • USA
  • May 25 2017

Addressing statutory estoppel issues in connection with inter partes re-examination, the US Court of Appeals for the Federal Circuit ordered the